Grace Therapeutics, Inc.
GRCE
$2.72
-$0.08-2.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -73.78% | -4.86% | 34.95% | 89.12% | 38.52% |
| Total Depreciation and Amortization | 100.00% | 0.00% | -85.71% | -87.50% | -90.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9,262.50% | -162.39% | -849.49% | -98.53% | -104.17% |
| Change in Net Operating Assets | -237.35% | 143.75% | 144.42% | 99.43% | 1,545.71% |
| Cash from Operations | -117.49% | -100.62% | 42.37% | 37.22% | 49.17% |
| Capital Expenditure | -- | -- | -- | -175.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.23% | -- | -- | 31.38% | -31.05% |
| Cash from Investing | 100.23% | -100.00% | -- | 31.17% | -31.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.46% | -179.12% | 42.15% | 172.95% | 2.75% |